Steroid minimization in pediatric renal transplantation: Early withdrawal or avoidance?
- 28 September 2010
- journal article
- review article
- Published by Wiley in Pediatric Transplantation
- Vol. 14 (8), 961-967
- https://doi.org/10.1111/j.1399-3046.2010.01403.x
Abstract
Clinically important adverse events associated with the use of corticosteroids post-transplantation include hypertension, dyslipidemia, impaired glucose metabolism (including diabetes mellitus), growth retardation, bone fractures, and cosmetic problems. Over recent years, a number of studies have investigated the effect of minimizing exposure to corticosteroids in post-transplant immunosuppression protocols in both adults and children. In pediatric patients, several different approaches have been evaluated, including late steroid withdrawal, early steroid withdrawal, and complete steroid avoidance with or without poly- or monoclonal antibody induction and a variety of maintenance immunosuppressants. This manuscript reviews the key studies and documents the specific clinical benefits associated with steroid minimization. The development of PTLD and bone marrow suppression has been a major safety concern in some of these studies. These studies and other adverse effects are discussed.Keywords
This publication has 26 references indexed in Scilit:
- Pediatric Kidney Transplantation Using a Novel Protocol of Rapid (6-Day) Discontinuation of Prednisone: 2-Year ResultsTransplantation, 2009
- Steroid-Free Immunosuppression Since 1999: 129 Pediatric Renal Transplants with Sustained Graft and Patient BenefitsAmerican Journal of Transplantation, 2009
- Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up dataPediatric Nephrology, 2009
- Pediatric Living Donor Kidney Transplantation Under Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 4-Year ExperienceTransplantation, 2008
- Can pediatric steroid‐free renal transplantation improve growth and metabolic complications?Pediatric Transplantation, 2008
- Recombinant growth hormone use pretransplant and risk for post‐transplant lymphoproliferative disease – A report of the NAPRTCSPediatric Transplantation, 2008
- Alemtuzumab (Campath 1H) Induction With Tacrolimus Monotherapy Is Safe for High Immunological Risk Renal TransplantationTransplantation, 2007
- Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantationThe Journal of Pediatrics, 2006
- One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipientTransplant International, 2005
- Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1Transplantation, 2003